Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 8/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850139 | 0.88 | BRAF (0.51) | GPR52BRAFMEN1KMT2ASCD | |
| SCHEMBL1853988 | 0.87 | GPR52 (0.53) | GPR52MAPTMEN1KMT2ASCD | |
| SCHEMBL1850856 | 0.84 | GPR52 (0.51) | GPR52MAPTMEN1KMT2ASCD | |
| SCHEMBL1850936 | 0.84 | STK17B (0.46) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL1850901 | 0.83 | STK17B (0.46) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL3219231 | 0.82 | GPR52 (0.69) | GPR52BRAFSCD | |
| SCHEMBL1848119 | 0.81 | GPR52 (0.71) | GPR52MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1848379 | 0.79 | GPR52 (0.69) | GPR52MAPTMEN1KMT2ASCD | |
| SCHEMBL1848416 | 0.79 | GPR52 (0.59) | GPR52MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3211107 | 0.79 | GPR52 (0.54) | GPR52MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885BRAF 4083/4885MAPT 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.